An Antibiotic Active against Dermatophytes, Derived from Bacillus Subtilis

Raubitschek, F.; Dostrovsky, A.

doi:10.1159/000257151

Cited by 21 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall, they exhibit surfactant activity similar to the iturins, but markedly decreased bioactivity. While bacillomycin D ( 6 ) has been found to strongly inhibit fungal growth and mediate biofilm formation in Bacillus amyloliquefaciens , bacillomycin F ( 7 ) has been shown to exert only weak antifungal and no antibacterial activity. ,− Bacillomycins L ( 8 ) and L c ( 9 ) show antifungal activity contributing to the antagonistic properties of B. subtilis against phytopathogenic fungi. ,,− Interestingly, the antifungal activity of the bacillomycins is strongly dependent on the chain length, supporting the idea that their mode of action is similar to that of the well-studied iturin A ( 2 ) …”

Section: Cyclic Lipopeptidesmentioning

confidence: 94%

“…The most common and first natural products described from B. subtilis were cyclic lipopeptides. − Their uncommon structure and potent bioactivity as well as surfactant activity made them attractive targets for isolation and structure elucidation. Their surfactant activity originates from their amphiphilic structure, created by a polar cyclic peptide backbone linked to a long branched or unbranched nonpolar alkyl chain.…”

Section: Cyclic Lipopeptidesmentioning

confidence: 99%

See 1 more Smart Citation

Bioactive Secondary Metabolites from Bacillus subtilis: A Comprehensive Review

2019

View full text Add to dashboard Cite

Bacillus subtilis is widely underappreciated for its inherent biosynthetic potential. This report comprehensively summarizes the known bioactive secondary metabolites from B. subtilis and highlights potential applications as plant pathogen control agents, drugs, and biosurfactants. B. subtilis is well known for the production of cyclic lipopeptides exhibiting strong surfactant and antimicrobial activities, such as surfactins, iturins, and fengycins. Several polyketide-derived macrolides as well as nonribosomal peptides, dihydroisocoumarins, and linear lipopeptides with antimicrobial properties have been reported, demonstrating the biosynthetic arsenal of this bacterium. Promising efforts toward the application of B. subtilis strains and their natural products in areas of agriculture and medicine are underway. However, industrial-scale availability of these compounds is currently limited by low fermentation yields and challenging accessibility via synthesis, necessitating the development of genetically engineered strains and optimized cultivation processes. We hope that this review will attract renewed interest in this often-overlooked bacterium and its impressive biosynthetic skill set.

show abstract

Section: Cyclic Lipopeptidesmentioning

confidence: 94%

Section: Cyclic Lipopeptidesmentioning

confidence: 99%

Bioactive Secondary Metabolites from Bacillus subtilis: A Comprehensive Review

2019

View full text Add to dashboard Cite

show abstract

“…The lawn-spotting technique was used to determine the antimicrobial spectrum of the B. pumilus (MSH) inhibitory substance (Raubitschek & Dostrovsky, 1950). The producer B. pumilus (MSH) strain was grown for 18-24 h on 5 % sheep-blood agar (BBL-Microbiology Systems), after which several haemolytic colonies were selected and superimposed individually onto lawns of test mycotic and bacterial isolates.…”

Section: Methodsmentioning

confidence: 99%

Production by Bacillus pumilus (MSH) of an antifungal compound that is active against Mucoraceae and Aspergillus species: preliminary report

Bottone

Peluso

2003

Journal of Medical Microbiology

View full text Add to dashboard Cite

A compound produced by Bacillus pumilus (MSH) that inhibits Mucoraceae and Aspergillus species is described. Fungicidal activity was demonstrated by lawn-spotting and by diffusion through 0·45 ìm Millipore membranes placed on 5 % sheep-blood agar, nutrient agar, trypticase soy agar and Mueller-Hinton agar, followed by spore inoculation of the bacterium-free underlying agar surface. With either technique, zones of fungal inhibition correlated with the zone of haemolysis produced by B. pumilus (MSH). The active compound inhibited Mucor and Aspergillus spore germination and aborted elongating hyphae, presumably by inducing a cell-wall lesion. Antifungal activity was stable in agar for a minimum of 8 days, resistant to Pronase degradation, and partially inactivated by chloroform exposure and at pH 5·6. Its molecular mass was determined by diffusion through dialysis membrane to be 500-3000 Da. Attempts at further isolation of the compound have proven unsuccessful to date.

show abstract

“…Bacillomycin D was discovered in 1950 by Raubitschek and Dostrovsky, on account of its strong activities against dermatophytes [1]. Several years later, this antifungal compound, produced by Bacillus subtilis, was shown to belong to the iturin lipopeptide family [2] and its amino acid sequence was determined [3,4].…”

Section: Introductionmentioning

confidence: 99%